Lower copays reduce expenses for patients now but could also protect drug-company profits.

After years of complaints about runaway drug costs, pharmaceutical companies are finally reducing the price of insulin. On March 1, Eli Lilly & Co. slashed some

Novartis Humira biosimilar’s high concentration gets approval in EU

The European Commission (EC) approved Novartis’ (NYSE:NVS) citrate-free high concentration formulation (HCF; 100 mg/mL) of Hyrimoz (adalimumab), a biosimilar to AbbVie’s (NYSE:ABBV) blockbuster drug Humira.

PLearning from Physicians Across Therapy Areas

Physician experiences with biosimilars have increased substantially in Europe over the past few years, driven by an increased policy focus, greater comfort, and regulatory guidance. These biosimilars have also provided savings for the overall